AstraZeneca published a New Scientist article detailing its oncology strategy to eliminate cancer as a cause of death.
Public source
Publisher name
Public post
At AstraZeneca, our bold ambition is to one day eliminate cancer as a cause of death, and I’m proud to be a part of a company that places so much emphasis on R&D. To ach…
Company
AstraZeneca
- Industry
- Pharmaceutical Manufacturing
- Location
- Cambridge, GB
- Company size
- 10,001+ employees
About AstraZeneca
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio
See moreLatest activity
Latest activity from AstraZeneca
141 signals
Presence & Recognition
AstraZeneca leaders share their vision for how continued scientific progress could transform what is possible by 2040 as they head into WCLC 2026
Presence & Recognition
AstraZeneca is reflecting on the future of lung cancer care ahead of WCLC 2026.
Research & Knowledge
AstraZeneca and partner Amgen announced positive high-level Phase III results from the DeLLphi-305 trial in extensive-stage small cell lung cancer.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
GSK
GSK published a new Custom Content article from The Wall Street Journal by Hesham A. Abdullah, MD, MSc and Chris Sheldon, PhD, sharing their approach to oncology business development.
Research & Knowledge
MSD in the UK
MSD in the UK published the report It’s About Time: Accelerating the Cancer Patient Pathway highlighting practical examples from Cancer Alliances supporting the National Cancer Plan ambitions.
Research & Knowledge
Jazz Pharmaceuticals
Jazz Pharmaceuticals is redefining the treatment of difficult-to-treat cancers by focusing on innovative areas of research like targeted therapy.
Research & Knowledge
Servier
Servier's R&D budget is 70% dedicated to oncology with a strong focus on rare cancers.
Research & Knowledge
Pfizer